| Document |
Document Title |
|
WO/2007/109882A1 |
The invention disclosed relates to the use of anti-glycation agents, such as (S)-isoproterenol, and its prodrug, (S)-isoproterenol dipivalate hydrochloride on the initiation of diabetic cataracts. (S)-Isoproterenol is a strong anti-glyca...
|
|
WO/2007/112358A1 |
The present invention provides a method for the synthesis of ß2-amino acids. The method also provides methods yielding a-substituted ß-amino aldehydes and ß-substituted γ-amino alcohols. The present method according to this invention...
|
|
WO/2007/107556A1 |
The present invention relates to the essentially enantiomerically pure compound of the formula I-R and to the essentially enantiomerically pure compound of the formula I-S and to a process for their preparation, and also to essentially e...
|
|
WO/2007/101872A1 |
The present invention relates to a process for the enantiomeric enrichment of salbutamol and salbutamol precursors and the acid-addition salts thereof: (I) where R is hydrogen or benzyl, R' is hydrogen or benzyl and X is CH2OH or COO-C1-...
|
|
WO/2007/099048A2 |
The invention relates to the use of polynuclear phenolic compounds with up to 20 bezene nuclei per molecule, obtained by reaction of a tetrahydrobenzoxazine I, where R1 = a hydrocarbon group and R2, R3, R4and R5 independently = H, OH, or...
|
|
WO/2007/098029A1 |
Processes for preparing amino alcohols or salts thereof and sulfonamide substituted alcohol compounds are provided. Desirably, the sulfonamide substituted alcohol compounds are heterocyclic sulfonamide trifluoroalkyl-substituted alcohol ...
|
|
WO/2007/097406A1 |
Disclosed is a method for converting a carbon cluster into a hydrophilic carbon cluster without greatly changing the characteristics of the carbon cluster. Also disclosed are a hydrophilic carbon cluster having a structure wherein a subs...
|
|
WO/2007/094806A1 |
Compositions and methods for making compositions including a quaternary trialkylammonium halide compound are described. Compositions follow the formula (I): wherein the R1 groups are each individually selected from alkyl groups having fr...
|
|
WO/2007/093514A1 |
The invention relates to a method for producing ethylene amines and ethanol amines by the hydrogenating amination of monoethylene glycol and ammonia in the presence of a catalyst. Said method is characterised in that it takes place in tw...
|
|
WO/2007/091070A1 |
A process for the preparation of a water soluble unsaturated fatty acid salt from a crude composition comprising at least one non-water soluble or sparingly water soluble unsaturated fatty acid or salt thereof, said process comprising: a...
|
|
WO/2007/092638A1 |
Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
|
|
WO/2007/088571A2 |
A process for resolving a compound in racemic form comprising the following steps is described: a) reacting a compound in racemic form with a resolving agent, b) forming a diastereoisomeric complex of the resolving agent and an enantiome...
|
|
WO/2007/082771A1 |
This invention relates to processes and intermediates for the stereoselective alkylation of carbonyl groups. The invention in particular allows the stereoselective preparation of the antidepressant drug escitalopram. It has been found th...
|
|
WO/2007/080463A1 |
The present invention relates to an improved process for the preparation of Dipyridamole of formula (I) by reacting 2,6-Dichloro-4, 8-dipiperidinopyrimido (5,4- d) pyrimidine (DDH) with Diethanolamine (DEA) using l-Methyl-2-pyrrolidinone...
|
|
WO/2007/077111A1 |
Compounds having bi-cyclic structure comprising a partially unsaturated 6-carbon first cyclic moiety interconnected to a 6-carbon second cyclic moiety second via a divalent linking moiety are provided. The compounds can be used as interm...
|
|
WO/2007/074068A1 |
The invention relates to a method for producing optically active, aromatically substituted amino ethanol of general formula (IIa) or (IIb), by reacting the corresponding chloroethanol of formula (Ia) or (Ib) with ammonia.
|
|
WO/2007/071404A1 |
Desvenlafaxine is formed from venlafaxine by the use of a demethylating agent comprising a metal sulfide, such as sodium sulfide, and optionally selenium.
|
|
WO/2007/073562A2 |
The present invention provides a metal chelator and methods that facilitate binding, detecting, monitoring and quantitating of heavy metal ions in a sample. This metal chelating moiety has the following formula (I).
|
|
WO/2007/062308A2 |
Compounds of formula (Ia) and (Ib) wherein A, B, C and R1 are described herein. The compounds (Ia) and (Ib) are useful as CETP inhibitors.
|
|
WO/2007/060122A1 |
The present invention relates to a process for preparing 3 amino-3-methyl-1-butanol (I) by, in a first step, reacting 3-methylbut-3-en-1-ol (IIa) or 3-methylbut-2-en-1-ol (IIb) with a nitrile of the formula (III) in the presence of an ac...
|
|
WO/2007/055180A1 |
Disclosed is a method for producing an optically active trans-2-aminocyclohexanol represented by the general formula (2) below or a protonic acid salt thereof. The method is characterized in that an optically active trans-2-benzylaminocy...
|
|
WO/2007/049579A1 |
Disclosed is a photopolymerizable composition containing a squarylium compound represented by the general formula (I) below, a radical initiator and a compound having an ethylenically unsaturated double bond. (I) [In the formula, R1 and ...
|
|
WO/2007/046001A2 |
Described is a process of preparing a pure solid or crystalline racemic 3,3- diarylpropylamine compound and the compounds formed thereof. The solid and crystalline forms of racemic 3,3-diarylpropylamine compound are especially suitable f...
|
|
WO/2007/045593A2 |
Compounds useful in the treatment of disorders characterised by deposits of amyloid aggregates are herein described together with pharmaceutical compounds containing the same. In particular the compounds of the present invention are thos...
|
|
WO/2007/039918A1 |
The present invention relates to a novel and improved process for the preparation of tolterodine of formula I. Key steps involved in the process are a vinyl Grignard reaction on a benzophenone derivative of formula XXI to get the vinyl c...
|
|
WO/2007/036712A1 |
The invention provides ionic liquids and processes for their preparation. The liquids may either comprise a cation of the formula (I); N+HR1R2R3 (I) wherein R1 is a group -R4-O-R5; R2 and R3 are each independently either hydrogen or hydr...
|
|
WO/2007/024954A1 |
This invention relates to compounds that are modulators of the liver X receptors (LXRs), and also to the methods for the making and use of such compounds.
|
|
WO/2007/022030A2 |
The present invention provides methods of carrying out the safe and reliable preparation of lipids comprising quaternary amines. Such lipids are especially suited for introducing therapeutic agents into cells or organisms. In particular,...
|
|
WO/2007/020204A2 |
This invention relates to stabilized aerosol solution formulations containing acid addition salts of salbutamol, which are suitable for administration by metered dose inhalers (MDIs). More particularly, this invention relates to solution...
|
|
WO/2007/017544A2 |
The invention relates to a method of obtaining 3,3-diphenylpropylamines (I), wherein R1 is H, alkyl, haloalkyl or alkoxyalkyl, R2 is alkyl, alkoxy, halogen, NO2, CN, CHO, which may be free or protected, CH2OH or COOR6, and R3 and R4 are ...
|
|
WO/2007/017267A2 |
Compounds of formula (I): are inhibitors of bacterial phenylalanyl t-RNA synthetase and are of use in treating bacterial infections.
|
|
WO/2007/018817A2 |
Alkanolamine compositions are disclosed. The composition comprises an alkanolamine and hydroxylamine or hydrazine. Preferred alkanolamine includes diethanolamine, triethanolamine, and mixtures thereof. The composition of the invention ha...
|
|
WO/2007/014973A2 |
The invention relates to a method of obtaining phenyl carbamates (I), wherein R1 is lower alkyl C1-C5 or benzyl and R2 is methyl, ethyl or propyl, consisting in reacting L-(S)-3-[(1-methylamino)ethyl]phenol, in the presence of a base, wi...
|
|
WO/2007/016495A2 |
The invention provides compounds of formulas (I), (II), and (III), methods of making them, and methods of their use. The compounds of the invention can be used as fluorescent sensors, for example, to detect an amine-containing analyte in...
|
|
WO/2007/011594A2 |
Highly selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including d...
|
|
WO/2007/009405A1 |
Racemic N-benzyl-N-methyl-3-(2-methylphenoxy)-3-phenylproρylamine (VIII) is an intermediate for obtaining atomoxetine. Racemic N-benzyl-N-methyl-3-(2-methylphenoxy)-3- phenylpropylamine (VIII) further reacts in a solution of an organic ...
|
|
WO/2007/009793A1 |
3-[2-(Dimethylamino)methyl(cyclohex-1-yl)]phenol fumarate is an analgesic with a very good action. The crystalline form B has proven to be very stable both chemically and physically and is particularly suitable for the production of the ...
|
|
WO/2007/009792A1 |
3-[2-(Dimethylamino)methyl(cyclohex-1-yl)]phenol maleate is an analgesic with a very good action. The crystalline form A has proven to be very stable both chemically and physically and is particularly suitable for the production of the a...
|
|
WO/2007/009794A1 |
The present invention relates to a crystalline salt of 3-[2-(dimethylamino)methyl(cyclohex-1-yl)]phenol and hydrogen chloride, preferably in a 1:1 composition, to various crystalline forms of this salt and to processes for preparing them...
|
|
WO/2007/007628A1 |
A choline salt crystal of (1S)-1,5-anhydro-1-[5-(azulen-2-ylmethyl)-2-hydroxyphenyl]- D-glucitol which shows an endothermic peak at 194 to 198°C as measured by differential scanning calorimetry (DSC analysis) and shows main peaks at abo...
|
|
WO/2007/007828A1 |
Disclosed is a novel compound useful as a production intermediate for benzylamine derivatives. Also disclosed is a method for producing such a compound. Specifically disclosed is a method for producing an ethylenediamine derivative repre...
|
|
WO/2007/003896A1 |
A compound that is useful for the treatment or prevention of a condition such as pain, that is associated with T-cell proliferation or that is mediated by pro- and/or anti-inflammatory cytokines, is of formula (I) wherein R1 is aryl or h...
|
|
WO/2007/000945A1 |
Disclosed is a method for producing a molded catalyst for continuous production of a mono(lower alkyl)monoalkanolamine wherein a binder is added into a catalyst raw material containing a crystalline metallosilicate and/or a layered clay ...
|
|
WO/2007/000334A1 |
A compound of formula (I), wherein A represents 2,3-dihydro-1-benzofuran-7-yl, 5-fluoro-2-methoxy-phenyl or 5-fluoro-2-hydroxy-phenyl; and R1 and R2 each independently represent hydrogen, fluorine or chlorine; or a physiologically functi...
|
|
WO/2007/000918A1 |
Benzylamine derivatives having structures represented by the general formula (1): (1) a method for the optical resolution of benzylamine derivatives which comprises using optically active mandelic acid as the reagent for optical resoluti...
|
|
WO/2006/133652A1 |
Compounds of the general formula (I), optical isomers, pharmaceutically acceptable salts, preparation process and uses thereof in which R1, R2, R3 and R4 are as defined in specification are disclosed. Such compounds can be optical isomer...
|
|
WO/2006/129688A1 |
Novel 2-aminobutanol compounds of the following general formula (I) excelling in immunosuppressive action, antirejection activity, etc. and relieved in bradycardia and other side effects, or their pharmaceutically acceptable acid adduct ...
|
|
WO/2006/122259A1 |
The invention relates to pure (R)-CMH and to the optical resolution of CMH- racemate, a key intermediate in the synthesis of (S)-Pregabalin. The invention also relates to the process for optically purifying (R)-CMH and to the process for...
|
|
WO/2006/121187A1 |
The present invention provides: an acrylicester compound having a structure represented by General Formula (1) or (2) below ; a latent electrostatic image forming member includes a cured material obtained through a radical polymerization...
|
|
WO/2006/117339A1 |
The invention relates to Mannich bases that can be produced from resorcinol, formaldehyde, and triethylenetetramine and/or tetraethylenepentamine. Also disclosed are a method for the production thereof and the use thereof as hardeners fo...
|
